Skip to NavigationSkip to content

Eli Lilly teams up with Chi-Med for Chinese sales of Elunate capsules

Published on 28/07/20 at 12:09pm

Eli Lilly Shanghai, an affiliate of the wider company, has enlisted the help of biopharma firm Hutchinson China MediTech, or Chi-Med, to commercialise its vascular endothelial growth factor receptor (VEGFR) 1/2/3 inhibitor therapy Elunate  (fruquintinib capsules) in the Chinese market, it has emerged.

The partnership kicks off in earnest from 1 October this year, from which date Chi-Med will handle all medical detailing, promotion and local and regional marketing activities related to Elunate. Lilly retains exclusive commercialisation rights for the drug and with continue to consolidate sales made in China.  

As part of the deal there will be no upfront payments, but both companies will share gross profits arising from successful sales targets in China, with Chi-Med eligible to receive an estimated total of between 70% and 80% of all Elunate sales in manufacturing costs, service payments, and royalties.

Chi-Med CEO Christian Hogg, CEO of Chi-Med and Julio Gay-Ger, President & General Manager of Lilly China, said in a joint statement: “After many years of constructive and successful collaboration, Lilly and Chi-Med believe that this agreement now establishes the optimal structure that will allow us to leverage the full resources of both companies to maximize the potential of Elunate in China.”

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches